The present study has a number of strengths, including the prospective nature of the sample collection, large numbers of NPC cases from both endemic and non-endemic regions in China, comprehensive assessment of both IgA and IgG antibodies against 16 EBV antigens, and measurement of HPyVs antibodies for control purposes. The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.